[Abstract] Mesenchymal stem cells (MSCs), first described in human bone marrow, are emerging as promising cell-based therapeutics for a wide range of diseases (Caplan and
were first reported by De Bari et al. (2001) . We previously reported that synovial MSCs have superior proliferation and chondrogenic potentials as compared to bone marrow-, muscle-, and adipose-derived MSCs in humans (Sakaguchi et al., 2005) and rats (Yoshimura et al., 2007) .
In addition, administration of synovial MSCs for osteochondral defect promoted cartilage regeneration in a rabbit (Koga et al., 2008 ) and a pig model (Nakamura et al., 2012) . In 2008, we started a clinical trial in human and obtained satisfactory results of symptoms and regenerated cartilage by Magnetic Resonance Imaging . We have also engaged in multiple research lines using synovial MSCs for meniscus regeneration in rats 7. Change the medium twice a week and culture for 2 weeks with α-MEM containing 10%
FBS with antibiotics.
Representative data
We can usually harvest 1 x 10 4 cells from one synovium (Figure 2) . After 2 weeks, we can obtain 5 x 10 5 -1 x 10 6 MSCs from one dish. The cells are heterogenous, and we usually use these cells of passage 2-4 in the experiments. We reported these data in our previous reports (Yoshimura et al., 2007) .
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